EXHIBIT 99.1


Alere Announces Update on Form 10-K and Provides Preliminary Unaudited Financial Results

WALTHAM, Mass., May 22, 2017 – Alere Inc. (NYSE: ALR), a global leader in rapid diagnostic tests, today announced certain preliminary unaudited financial information for the fourth quarter and full fiscal year ended December 31, 2016 and the first quarter of 2017 ended March 31, 2017. The Company also provided an update on its expected filing of its 2016 Annual Report on Form 10-K and filed its preliminary proxy statement with respect to the pending merger with Abbott Laboratories.
The following amounts are preliminary, unaudited and are subject to change and reflect the impact of the Restatement (as defined below) adjustments identified to date, as described further below:   
Preliminary Unaudited Full Year 2016 Results
Revenue for the full year 2016 is expected to be $2.38 billion, which would be a decrease from $2.45 billion in full year 2015.
 
GAAP loss from continuing operations is expected to be $(140) million, or $(1.86) per diluted share, for the full year 2016.
 
Non-GAAP organic growth for the full year 2016 is expected to be +0.3% or +2.5% excluding Arriva*.
Non-GAAP adjusted EBITDA is expected to be $344 million for the full year 2016, including approximately $135 million in merger-related costs, audit and legal fees related to ongoing investigations and legal settlements, as detailed in the Supplemental Financial Information table.
*During the period from November 4, 2016 to December 31, 2016, the Company furnished $9.8 million of Arriva products and services that were subject to the CMS revocation to customers but did not recognize any revenue for such products and services because they were not eligible for reimbursement by CMS at the time the Company furnished them.
Preliminary Unaudited Fourth Quarter 2016 Results
Total revenue is expected to be $597 million, which would be a decrease from $617 million in the prior year period.
Reported GAAP loss from continuing operations during the fourth quarter of 2016 is expected to be $(117) million, or $(1.41) per diluted share.
Non-GAAP organic growth during the fourth quarter of 2016 is expected to be -0.9%, or +3.7% excluding Arriva.
 
 

Non-GAAP adjusted EBITDA is expected to be $79 million in the fourth quarter of 2016, which includes approximately $50 million in merger-related costs, audit and legal fees related to ongoing investigations and legal settlements, as detailed in the Supplemental Financial Information table.

Preliminary Unaudited First Quarter 2017 Results
Total revenue is expected to be $588 million.
Non-GAAP organic growth is expected to be +0.9%, or +6.8% excluding Arriva.

Update on Annual Report 2016 Form 10-K
As previously disclosed, the Company was delayed in filing its Annual Report on Form 10-K for the fiscal year ended December 31, 2016 due to the Company’s review of certain revenue transactions in the Company’s South Korea and Japan locations. Based on this review, the Company determined that it had incorrectly recorded certain revenue transactions at its Standard Diagnostics subsidiary in South Korea. Specifically, the Company failed to correctly apply U.S. GAAP regarding the timing of revenue recognition primarily relating to transactions in which the Company recognized revenue prior to full satisfaction of all contractual criteria for title and risk of loss passing to the customer as required by U.S. GAAP. The principal cause of these misstatements in the timing of revenue recognition was inappropriate conduct at the Company’s Standard Diagnostics subsidiary.  As also previously disclosed, as a result of this review, the Company will be restating certain previously issued financial statements (the “Restatement”).
The Company has completed its review of the above matters at its South Korea and Japan locations and, consistent with its prior expectation, the Company expects the following adjustments to previously reported financial information as set forth in the tables below. In addition, the Restatement reflects corrections for certain other misstatements that the Company identified in 2017 relating to 2014, 2015 and 2016. These adjustments relate to (a) misstatements in the classification of certain amounts between current assets, noncurrent assets and current liabilities, (b) misstatements in the classification of certain legal-related charges between non-operating expenses and operating expenses, and (c) misstatements to general and administrative expenses to correct the timing of bad debt expenses and fair value adjustments related to contingent consideration liabilities from acquisitions. These adjustments are incorporated into the tables below.
 
   
Nine Months
   
Twelve Months
   
Twelve Months
   
Twelve Months
 
Annual Restatement Impact
(in millions)
 
Ended
September 30, 2016
   
Ended
December 31, 2015
   
Ended
December 31, 2014
   
Ended
December 31, 2013
 
                         
Revenue
 
$
8
   
$
(8
)
 
$
2
   
$
(1
)
Pre-Tax Income
 
$
(1
)
 
$
(4
)
 
$
0
   
$
1
 
Net Income
 
$
(0
)
 
$
(3
)
 
$
0
   
$
0
 
                                 
   
Three Months
   
Three Months
   
Three Months
   
Three Months
 
2015 Quarterly Restatement Impact
(in millions)
 
Ended
March 31, 2015
   
Ended
June 30, 2015
   
Ended
September 30, 2015
   
Ended
December 31, 2015
 
                                 
Revenue
 
$
(3
)
 
$
(1
)
 
$
1
   
$
(6
)
Pre-Tax Income
 
$
(1
)
 
$
(0
)
 
$
1
   
$
(4
)
Net Income
 
$
(0
)
 
$
(0
)
 
$
1
   
$
(3
)
                                 
   
Three Months
   
Three Months
   
Three Months
         
2016 Quarterly Restatement Impact
(in millions)
 
Ended
March 31, 2016
   
Ended
June 30, 2016
   
Ended
September 30, 2016
         
                                 
Revenue
 
$
9
   
$
(1
)
 
$
(0
)
       
Pre-Tax Income
 
$
4
   
$
2
   
$
(6
)
       
Net Income
 
$
4
   
$
2
   
$
(6
)
       

NOTE: The ($6) million pre-tax income impact for the Three Months Ended September 30, 2016 includes $4.4M of expense related to fair value adjustments for contingent consideration.
2


In addition, as the Company disclosed on May 11, 2017, it is in the process of reviewing sales transactions to a limited number of distributors from select selling entities during fiscal years 2012 to 2016 to determine if revenue recognition timing was appropriate according to U.S. GAAP with respect to collectability being reasonably assured at the time of sale. This review relates to the timing of the recognition of the revenue and not to the existence or measurement of revenue for these transactions and the selling entities being reviewed have historical collection rates in excess of 99.5%. 
The Company’s goal is to complete its review and file its 2016 Annual Report on Form 10-K by no later than June 15, 2017.
The review necessary to complete the 2016 Annual Report on Form 10-K is not complete.  The time necessary to review the foregoing matter may take longer than the Company expects, which would cause a further delay in the filing of the Annual Report beyond the projected filing date noted above. In the course of this ongoing review of revenue recognition and the completion of the review necessary to file the Annual Report, the Company may identify other matters that require additional time to review, which other matters may be similar or different to those identified above.  In addition, any of these other items may require the Company to further adjust previously reported financial information, and such adjustments may be material in amount.
Information Regarding Preliminary Unaudited Results
The financial results presented in this release are preliminary and may change. These preliminary results include calculations that have been prepared by Alere management and have not been reviewed or audited by our independent registered public accounting firm. There can be no assurance that Alere's actual financial results will not materially differ from the preliminary unaudited financial data presented herein. Actual results may differ for a number of reasons, including the impact of any changes that may be required as a result of the ongoing review by Alere of revenue recognition and other adjustments that may be made in connection with the finalization of the fiscal year 2016 financial statements and the finalization of the financial statements for the three months ended March 31, 2017 (which may also impact the financial results for any other period presented herein).  In addition, the preliminary unaudited financial data presented for the periods ended December 31, 2016 and March 31, 2017 should not be viewed as a substitute for the full financial information prepared in accordance with U.S. GAAP, including footnotes, which is expected to be filed with the SEC as soon as practicable.  Please see the "2016 Form 10-K Update" and "Cautionary Statement Regarding Forward-Looking Statements" sections of this press release for further information.
3

Non-GAAP Information
To supplement the financial measures prepared in accordance with U.S. GAAP, the Company uses Non-GAAP adjusted EBITDA and organic growth, which are non-GAAP financial measures.  The reconciliations of Non-GAAP adjusted EBITDA to net income (loss) from continuing operations and organic growth to revenue, the most directly comparable financial measure calculated and presented in accordance with U.S. GAAP, is shown in the table in this press release. The Company believes Non-GAAP adjusted EBITDA and organic growth are useful to investors because these metrics are commonly used by investors to assess the unleveraged, pre-tax financial performance and operating results of ongoing business operations. The Company’s management also uses Non-GAAP adjusted EBITDA and organic growth because the Company’s management also believes that these are useful measures to evaluate the performance of the Company based on operational factors. It should also be noted that not all companies calculate Non-GAAP adjusted EBITDA and organic growth in the same manner and, accordingly, these measures presented in this press release may not be comparable to similar measures used by other companies.

Cautionary Statement Regarding Forward-Looking Statements
This communication contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Readers can identify these statements by forward-looking words such as “preliminary”, “may,” “could,” “should,” “would,” “intend,” “will,” “expect,” “anticipate,” “believe,” “estimate,” “can,” “continue” or similar words. A number of important factors could cause actual results of Alere and its subsidiaries to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, (i) the risk that the proposed merger with Abbott Laboratories (“Abbott”) may not be completed in a timely manner or at all; (ii) the failure to receive, on a timely basis or otherwise, the required approval of the proposed merger with Abbott by Alere’s stockholders, (iii) the possibility that competing offers or acquisition proposals for Alere will be made; (iv) the possibility that any or all of the various conditions to the consummation of the merger may not be satisfied or waived, including the failure to receive any required regulatory approvals from any applicable governmental entities (or any conditions, limitations or restrictions placed on such approvals); (v) the occurrence of any event, change or other circumstance that could give rise to the termination of the Agreement and Plan of Merger, as amended (the “Merger Agreement”) among Alere and Abbott pursuant to which Abbott will acquire Alere, including in circumstances which would require Alere to pay a termination fee or other expenses; (vi) the effect of the announcement or pendency of the transactions contemplated by the Merger Agreement on Alere’s ability to retain and hire key personnel, its ability to maintain relationships with its customers, suppliers and others with whom it does business, or its operating results and business generally; (vii) risks related to diverting management’s attention from Alere’s ongoing business operations; (viii) the risk that stockholder litigation in connection with the transactions contemplated by the Merger Agreement may result in significant costs of defense, indemnification and liability, (ix) the risk that the previously announced review of certain aspects of revenue recognition is not completed in a timely manner or the scope of such review expands, (x) the risk that the failure by Alere to file its Form 10-K for the fiscal year ended December 31, 2016 and Form 10-Q for the fiscal quarter ended in March 31, 2017 in a timely manner could lead to the acceleration of the maturity of certain of Alere’s indebtedness, (xi) the possibility that the previously announced review of certain aspects of revenue recognition uncovers an additional error or errors in revenue recognition or other financial information which require additional adjustments which may be material, or material weaknesses in the Company’s internal controls over financial reporting, (xii) the risk that the Company experiences an acceleration of amounts due under its senior secured credit facility due to the restatement, any circumstances described in Alere’s Current Report on Form 8-K as filed on April 17, 2017, this Current Report on Form 8-K or the failure to timely file the Annual Report on Form 10-K for 2016 and Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2017 (or that the Company could be required to obtain a waiver under such credit agreement), (xiii) risks relating to the ongoing investigations by the United States Securities and Exchange Commission (the “SEC”) and the United States Department of Justice, (xiv) the risk that these or other risk factors impact the expected timing of the filing of the Form 10-K for the fiscal year ended December 31, 2016 and Form 10-Q for the fiscal
4

quarter ended in March 31, 2017, and (xv) the risk factors detailed in Part I, Item 1A, “Risk Factors,” of our Annual Report on Form 10-K for the fiscal year ended December 31, 2015 (as filed with the SEC on August 8, 2016) and other risk factors identified herein or from time to time in our periodic filings with the SEC. Readers should carefully review these risk factors, and should not place undue reliance on our forward-looking statements. These forward-looking statements are based on information, plans and estimates at the date of this communication. The Company undertakes no obligation to update any forward-looking statements to reflect changes in underlying assumptions or factors, new information, future events or other changes.
About Alere
Alere believes that when diagnosing and monitoring health conditions, Knowing now matters.™  Alere delivers reliable and actionable information by providing rapid diagnostic tests, enhancing clinical and economic healthcare outcomes globally. Headquartered in Waltham, Mass., Alere focuses on rapid diagnostics for cardiometabolic disease, infectious disease and toxicology. For more information on Alere, please visit www.alere.com.

# # #


Investor Relations
Juliet Cunningham
Vice President, Investor Relations
ir@alere.com
858.805.2232

5

Alere Inc. and Subsidiaries
Preliminary Unaudited Condensed Consolidated Statements of Operations
(in thousands, except per share amounts)

    
Three Months Ended December 31,
   
Twelve Months Ended December 31,
 
   
2016
   
2015
   
2016
   
2015
 
                         
Net product sales and services revenue
 
$
592,553
   
$
613,850
   
$
2,364,337
   
$
2,438,638
 
License and royalty revenue
   
4,256
     
3,286
     
11,998
     
16,977
 
Net revenue
   
596,809
     
617,136
     
2,376,335
     
2,455,615
 
Cost of net revenue
   
325,648
     
368,586
     
1,286,468
     
1,347,315
 
      Gross profit
   
271,161
     
248,550
     
1,089,867
     
1,108,300
 
      Gross margin
   
45
%
   
40
%
   
46
%
   
45
%
                                 
Operating expenses:
                               
Research and development
   
25,184
     
28,228
     
112,122
     
119,453
 
Selling, general and administrative
   
264,283
     
229,877
     
969,683
     
808,595
 
Impairment and (gain) loss on disposition, net
   
-
     
8,132
     
(3,810
)
   
50,540
 
      Operating income
   
(18,306
)
   
(17,687
)
   
11,872
     
129,712
 
Interest and other income (expense), net
   
(32,137
)
   
(60,482
)
   
(167,122
)
   
(214,254
)
Loss from continuing operations before provision (benefit) for income taxes
   
(50,443
)
   
(78,169
)
   
(155,250
)
   
(84,542
)
Provision (benefit) for income taxes
   
83,762
     
(51,146
)
   
35,376
     
(53,564
)
Income (loss) from continuing operations before equity earnings of unconsolidated entities, net of tax
   
(134,205
)
   
(27,023
)
   
(190,626
)
   
(30,978
)
Equity earnings of unconsolidated entities, net of tax
   
17,200
     
5,210
     
50,505
     
15,530
 
Income (loss) from continuing operations
   
(117,005
)
   
(21,813
)
   
(140,121
)
   
(15,448
)
Income from discontinued operations, net of tax
   
-
     
2,736
     
-
     
219,513
 
Net income
   
(117,005
)
   
(19,077
)
   
(140,121
)
   
204,065
 
Less: Net income attributable to non-controlling interests
   
(103
)
   
(5
)
   
350
     
381
 
Net income attributable to Alere Inc. and Subsidiaries
   
(116,902
)
   
(19,072
)
   
(140,471
)
   
203,684
 
                                 
Preferred stock dividends
   
(5,367
)
   
(5,367
)
   
(21,350
)
   
(21,293
)
                                 
Net income available to common stockholders
 
$
(122,269
)
 
$
(24,439
)
 
$
(161,821
)
 
$
182,391
 
                                 
Basic net income per common share:
                               
  Income (loss) from continuing operations
 
$
(1.41
)
 
$
(0.31
)
 
$
(1.86
)
 
$
(0.43
)
  Income from discontinued operations
   
-
                     
2.57
 
      Basic and diluted net income per common share
 
$
(1.41
)
 
$
(0.31
)
 
$
(1.86
)
 
$
2.14
 
                                 
Diluted net income per common share:
                               
  Income (loss) from continuing operations
 
$
(1.41
)
 
$
(0.31
)
 
$
(1.86
)
 
$
(0.43
)
  Income from discontinued operations
   
-
             
-
     
2.57
 
      Diluted net income per common share
 
$
(1.41
)
 
$
(0.31
)
 
$
(1.86
)
 
$
2.14
 
                                 
Weighted average shares - basic
   
86,955
     
85,953
     
86,796
     
85,420
 
Weighted average shares - diluted
   
86,955
     
85,953
     
86,796
     
85,420
 

 
6

Alere Inc. and Subsidiaries
Preliminary Unaudited Condensed Consolidated Balance Sheets
(in thousands)

   
December 31,
   
December 31,
 
   
2016
   
2015
 
ASSETS
           
CURRENT ASSETS:
           
Cash and cash equivalents1
 
$
567,215
   
$
502,200
 
Restricted cash
   
51,550
     
5,694
 
Marketable securities
   
76
     
164
 
Accounts receivable, net
   
413,535
     
436,924
 
Inventories, net
   
308,920
     
350,949
 
Prepaid expenses and other current assets
   
118,607
     
114,514
 
Assets held for sale
   
-
     
4,165
 
Total current assets
   
1,459,903
     
1,414,610
 
                 
Property, Plant and Equipment, net
   
441,190
     
446,039
 
Goodwill and other intangible assets, net
   
3,592,107
     
3,862,306
 
Restricted Cash- non-current
   
2,171
     
43,228
 
Other non-current assets
   
152,908
     
138,640
 
Assets held for sale - non-current
   
-
     
13,337
 
Total assets
 
$
5,648,279
   
$
5,918,160
 
                 
LIABILITIES AND STOCKHOLDERS' EQUITY
               
CURRENT LIABILITIES:
               
Short-term debt and current portions of long-term debt and capital lease obligations
 
$
85,434
   
$
203,954
 
Liabilities related to assets held for sale
   
-
     
363
 
Other current liabilities
   
593,574
     
518,389
 
Total current liabilities
   
679,008
     
722,706
 
                 
LONG-TERM LIABILITIES:
               
Long-term debt and capital lease obligations, net of current portions
   
2,865,426
     
2,838,347
 
Deferred tax liabilities
   
119,098
     
147,618
 
Other long-term liabilities
   
155,992
     
154,193
 
Liabilities related to assets held for sale - non-current
   
-
     
-
 
Total long-term liabilities
   
3,140,516
     
3,140,158
 
                 
TOTAL EQUITY
   
1,828,755
     
2,055,296
 
Total liabilities and equity
 
$
5,648,279
   
$
5,918,160
 

1)
As of December 31, 2016 the Company held $567M of cash and cash equivalents, $172M was held by domestic subsidaries and $395M was held by foreign entities.

 
7

Alere Inc. and Subsidiaries
Preliminary Unaudited Selected Consolidated Revenues
(in thousands)

   
Three Months Ended December 31,
   
% Change
 
   
2016
   
2015
     
2016 v. 2015
 
Professional diagnostics segment (1)
                   
Cardiometabolic
 
$
143,569
   
$
180,163
     
-20
%
Infectious disease
   
211,509
     
188,609
     
12
%
Toxicology
   
147,785
     
149,540
     
-1
%
Other
   
38,020
     
44,927
     
-15
%
Total professional diagnostics segment
   
540,883
     
563,239
     
-4
%
Consumer diagnostics segment (1)
   
17,569
     
19,768
     
-11
%
Other Non-reportable
   
34,101
     
30,843
     
11
%
License and royalty revenue
   
4,256
     
3,286
     
30
%
Net revenue
 
$
596,809
   
$
617,136
     
-3
%
                         
                         
                         
   
Twelve Months Ended December 31,
   
% Change
 
     
2016
     
2015
     
2016 v. 2015
 
Professional diagnostics segment (1)
                       
Cardiometabolic
 
$
622,468
   
$
703,553
     
-12
%
Infectious disease
   
776,153
     
710,178
     
9
%
Toxicology
   
608,635
     
618,362
     
-2
%
Other
   
140,426
     
192,321
     
-27
%
Total professional diagnostics segment
   
2,147,682
     
2,224,414
     
-3
%
Consumer diagnostics segment (1)
   
74,152
     
85,128
     
-13
%
Other Non-reportable
   
142,503
     
129,096
     
10
%
License and royalty revenue
   
11,998
     
16,977
     
-29
%
Net revenue
 
$
2,376,335
   
$
2,455,615
     
-3
%

(1)
Revenues have been restated for the impact of restatement adjustments made during the preparation of our consolidated financial statements for 2016.

 
8

Alere Inc. and Subsidiaries
Preliminary Unaudited Reconciliation of Net Income (Loss) to Non-GAAP EBITDA
(in thousands)

   
Three Months Ended December 31,
 
   
2016
   
2015
 
             
Net Income (loss) (1)
 
$
(117,005
)
 
$
(19,077
)
  Less: Income from discontinued operations, net of tax
   
-
     
2,736
 
Loss from continuing operations
   
(117,005
)
   
(21,813
)
                 
Adjustment related to acquired software license contracts
   
-
     
-
 
Income tax provision (benefit)
   
83,762
     
(51,146
)
Depreciation and amortization
   
71,467
     
75,719
 
Interest, net
   
42,342
     
57,954
 
Non-cash stock-based compensation expense
   
10,681
     
6,795
 
Non-cash fair value adjustments to acquisition-related contingent consideration
   
(1,419
)
   
(5,703
)
Impairment and (gain) loss on dispositions, net
   
(11,152
)
   
8,132
 
Non-cash InRatio product recall expenses
   
-
     
21,100
 
Other
   
-
     
(40
)
Non-GAAP Adjusted EBITDA
 
$
78,676
   
$
90,998
 

(1)
Net income (loss) for the three months ended December 31, 2015 includes  $16.7 million of cash costs asssociated with the voluntary withdrawal of InRatio product, restructuring charges of $4.3 million, $2.8 million of costs associated with business dispositions, $0.1 million of acquisition-related costs which have not been added back for purposes of computing Non-GAAP Adjusted EBITDA.  The three months ended December 31, 2016 includes $22.1 million of Abbott integration costs, $14.3 million for a legal settlement accrual, $12.8 million of charges related to governmental investigations, non-interest related restructuring charges of $10.1 million,  $0.5 million of cash costs associated with the voluntary withdrawal of InRatio product, and $0.1 million of acquisition-related costs which have not been added back for purposes of computing Non-GAAP Adjusted EBITDA.
 

   
Twelve Months Ended December 31,
 
   
2016
   
2015
 
             
Net Income (loss) (1)
 
$
(140,121
)
 
$
204,065
 
  Less: Income from discontinued operations, net of tax
   
-
     
219,513
 
Loss from continuing operations
   
(140,121
)
   
(15,448
)
                 
Adjustment related to acquired software license contracts
   
-
     
877
 
Income tax provision (benefit)
   
35,376
     
(53,564
)
Depreciation and amortization
   
285,884
     
309,684
 
Interest, net
   
168,320
     
212,551
 
Non-cash stock-based compensation expense
   
41,796
     
26,391
 
Non-cash fair value adjustments to acquisition-related contingent consideration
   
(13,308
)
   
(57,613
)
Impairment and (gain) loss on dispositions, net
   
(33,683
)
   
50,540
 
Non-cash InRatio product recall expenses
   
-
     
21,100
 
Other
   
-
     
622
 
Non-GAAP Adjusted EBITDA
 
$
344,264
   
$
495,139
 

(1)
Net income (loss) for the twelve months ended December 31, 2015 includes $16.7 million of cash costs associated with the voluntary withdrawal of InRatio product, restructuring charges of $15.6 million, $9.3 million of costs associated with business dispositions, and $0.5 million of acquisition-related costs which have not been added back for purposes of computing Non-GAAP Adjusted EBITDA.  The twelve months ended December 31, 2016 includes $60.3 million of Abbott integration costs, restructuring charges of $37.9 million, $35.2 million for a legal settlement accrual, $35.6 million of charges related to governmental investigations, $6.0 million of acquisition-related costs, $1.8 million of cash costs associated with the withdrawal of InRatio product and $1.0 million of costs associated with business dispositions which have not been added back for purposes of computing Non-GAAP Adjusted EBITDA.


9

Alere Inc. and Subsidiaries
Preliminary Unaudited Reconciliation of Non-GAAP Organic Revenue Growth
(in thousands)

   
Three Months Ended December 31,
   
% Change
 
   
2016
   
2015
     
2016 v. 2015
 
                     
Net revenue
 
$
596,809
   
$
617,136
     
-3.3
%
Impact of foreign currency exchange
   
7,830
     
-
         
Impact of acquisitions & dispositions
   
(1,453
)
   
(8,234
)
       
Non-GAAP organic net revenue
 
$
603,186
   
$
608,902
     
-0.9
%
                         
Arriva Revenue
   
(11,622
)
   
(38,592
)
       
Non-GAAP organic net revenue (excluding Arriva)
 
$
591,564
   
$
570,310
     
3.7
%
                         
                         
                         
   
Twelve Months Ended December 31,
   
% Change
 
     
2016
     
2015
     
2016 v. 2015
 
                         
Net revenue
 
$
2,376,335
   
$
2,455,615
     
-3.2
%
Impact of foreign currency exchange
   
40,543
     
-
         
Impact of acquisitions & dispositions
   
(13,984
)
   
(60,414
)
       
Non-GAAP organic net revenue
 
$
2,402,894
   
$
2,395,201
     
0.3
%
                         
Arriva Revenue
   
(99,887
)
   
(148,538
)
       
Non-GAAP organic net revenue (excluding Arriva)
 
$
2,303,007
   
$
2,246,663
     
2.5
%
 
 
10

Alere Inc. and Subsidiaries
Preliminary Unaudited Consolidated Statements of Cash Flows
(in thousands)

   
For The Year Ended December 31,
 
   
2016
   
2015
   
2014
 
Cash Flows from Operating Activities:
                 
Net income (loss)
 
$
(140,121
)
 
$
204,065
   
$
(33,123
)
Income from discontinued operations, net of tax
   
     
219,513
     
138,318
 
Income (loss) from continuing operations
   
(140,121
)
   
(15,448
)
   
(171,441
)
Adjustments to reconcile net income (loss) from continuing operations to net cash provided by operating activities:
                       
Non-cash interest expense, including amortization of original issue discounts and deferred financing costs
   
13,369
     
12,831
     
16,233
 
Depreciation and amortization
   
285,608
     
309,264
     
336,029
 
Non-cash stock-based compensation expense
   
41,796
     
26,391
     
12,452
 
Tax benefit related to discontinued operations retained by Alere Inc.
   
     
     
9,845
 
Impairment of inventory
   
2,667
     
15,597
     
3,124
 
Impairment of long-lived assets
   
1,792
     
3,708
     
7,019
 
Loss on sale of fixed assets
   
3,551
     
3,925
     
6,545
 
Equity earnings of unconsolidated entities, net of tax
   
(50,505
)
   
(15,530
)
   
(17,509
)
Deferred income taxes
   
(36,010
)
   
(99,389
)
   
12,254
 
Loss on extinguishment of debt
   
     
19,886
     
 
Impairment and net (gain) loss on business disposition
   
(3,810
)
   
50,540
     
7,742
 
Other non-cash items
   
(463
)
   
28,782
     
4,965
 
Non-cash change in fair value of contingent consideration
   
(13,309
)
   
(59,871
)
   
7,677
 
Changes in assets and liabilities, net of acquisitions:
                       
Accounts receivable, net
   
26,698
     
(6,680
)
   
(4,264
)
Inventories, net
   
(13,655
)
   
(63,935
)
   
(67,532
)
Prepaid expenses and other current assets
   
(19,921
)
   
(5,295
)
   
(51,998
)
Accounts payable
   
4,362
     
(10,783
)
   
47,851
 
Accrued expenses and other current liabilities
   
54,342
     
22,643
     
37,886
 
Other non-current assets and liabilities
   
23,329
     
(3,357
)
   
13,254
 
Cash paid for contingent consideration
   
(430
)
   
(6,315
)
   
(22,077
)
Net cash provided by continuing operations
   
179,290
     
206,964
     
188,055
 
Net cash provided by discontinued operations
   
     
318
     
43,468
 
Net cash provided by operating activities
   
179,290
     
207,282
     
231,523
 
                         
Cash Flows from Investing Activities:
                       
Increase in restricted cash
   
(4,721
)
   
(13,715
)
   
(5,446
)
Purchases of property, plant and equipment
   
(67,694
)
   
(90,778
)
   
(100,562
)
Proceeds from sale of property, plant and equipment
   
1,428
     
2,099
     
1,486
 
Cash received from business dispositions, net of cash divested
   
21,470
     
675,823
     
45,076
 
Cash paid for business acquisitions, net of cash acquired
   
(5,958
)
   
(60,135
)
   
(75
)
Cash received from investments
   
     
     
198
 
Cash paid for equity investment
   
(184
)
   
     
 
Proceeds from sale of equity investment
   
40,751
     
     
8,546
 
Cash received from sales of marketable securities
   
87
     
92
     
580
 
Cash received from equity method investments
   
16,989
     
26,136
     
980
 
Decrease (increase) in other assets
   
460
     
(1,794
)
   
986
 
Net cash provided by (used in) continuing operations
   
2,628
     
537,728
     
(48,231
)
Net cash used in discontinued operations
   
     
(209
)
   
(8,972
)
Net cash provided by (used in) investing activities
   
2,628
     
537,519
     
(57,203
)
                         
Cash Flows from Financing Activities:
                       
Cash paid for financing costs
   
(29,187
)
   
(16,188
)
   
(1,528
)
Cash paid for contingent consideration
   
(680
)
   
(14,223
)
   
(32,902
)
Cash paid for dividends
   
(21,292
)
   
(21,293
)
   
(21,293
)
Proceeds from issuance of common stock, net of issuance costs
   
18,934
     
79,185
     
51,555
 
Proceeds from issuance of short-term debt
   
     
1,511
     
806
 
Proceeds from issuance of long-term debt
   
459
     
2,162,162
     
58
 
Payments on short-term debt
   
(1,722
)
   
(25,584
)
   
 
Payments on long-term debt
   
(198,316
)
   
(2,656,386
)
   
(65,122
)
Net proceeds (payments) under revolving credit facilities
   
126,017
     
(127,536
)
   
(42,522
)
Excess tax benefits on exercised stock options
   
     
     
972
 
Principal payments on capital lease obligations
   
(4,032
)
   
(5,618
)
   
(6,085
)
Purchase of non-controlling interest
   
     
     
(623
)
Other
   
     
(8,937
)
   
 
Net cash used in continuing operations
   
(109,819
)
   
(632,907
)
   
(116,684
)
Net cash used in discontinued operations
   
     
(76
)
   
(1,471
)
Net cash used in financing activities
   
(109,819
)
   
(632,983
)
   
(118,155
)
Foreign exchange effect on cash and cash equivalents
   
(7,084
)
   
(11,379
)
   
(16,312
)
Net increase in cash and cash equivalents
   
65,015
     
100,439
     
39,853
 
Cash and cash equivalents, beginning of period – continuing operations
   
502,200
     
378,461
     
355,431
 
Cash and cash equivalents, beginning of period – discontinued operations
   
     
23,300
     
6,477
 
Cash and cash equivalents, end of period
   
567,215
     
502,200
     
401,761
 
Less: Cash and cash equivalents of discontinued operations, end of period
   
     
     
23,300
 
Cash and cash equivalents of continuing operations, end of period
 
$
567,215
   
$
502,200
   
$
378,461
 

11

Alere Inc. and Subsidiaries
Preliminary Unaudited Supplemental Financial Information
(in thousands, except per share amounts)

   
Three months ended December 31, 2016
 
   
Cost of Net Revenue
   
Research and Development
   
Selling, General & Administrative
   
Impairment, net of loss on disposition
   
Interest and other income, net
   
Provision for income taxes
   
Equity earnings of unconsolidated entities, net of tax
   
Net Income1
 
                                                 
Amortization of acquisition-related intangible assets
 
$
12,281
   
$
922
   
$
31,384
   
$
-
   
$
-
   
$
-
   
$
-
   
$
(44,587
)
Restructuring charges
   
2,090
     
512
     
7,535
     
-
     
-
     
-
     
-
     
(10,136
)
Impairment  Charges
   
-
     
-
     
193
     
-
     
-
     
-
     
-
     
(193
)
Stock-based compensation expense
   
518
     
531
     
9,633
     
-
     
-
     
-
     
-
     
(10,681
)
Acquisition-related costs
   
-
     
-
     
72
     
-
     
-
     
-
     
-
     
(72
)
Fair value adjustments to acquisition-related contingent consideration
   
-
     
-
     
(1,419
)
   
-
     
-
     
-
     
-
     
1,419
 
Costs associated with potential business dispositions
   
-
     
-
     
42
     
-
     
-
     
-
     
-
     
(42
)
Impairment and (gain) loss on disposition, net
   
-
     
-
     
-
     
-
     
-
     
-
     
(11,152
)
   
11,152
 
Amortization - Unconsolidated Subs
   
-
     
-
     
-
     
-
     
-
     
-
     
46
     
(46
)
Audit and legal fees related to on-going governmental investigations
   
-
     
-
     
12,893
     
-
     
1,697
     
-
     
-
     
(14,590
)
Abbott transaction related expenses
   
-
     
-
     
22,064
     
-
     
-
     
-
     
-
     
(22,064
)
INRatio recall expense
   
2,481
     
-
     
(1,300
)
   
-
     
-
     
-
     
-
     
(1,181
)
Legal settlement accrual
   
-
     
-
     
14,300
     
-
     
-
     
-
     
-
     
(14,300
)
Income tax effects on items above
   
-
     
-
     
-
     
-
     
-
     
72,986
     
-
     
(72,986
)
 Total of Supplemental Information
 
$
17,370
   
$
1,965
   
$
95,398
   
$
-
   
$
1,697
   
$
72,986
   
$
(11,106
)
 
$
(178,309
)
                                                                 
Impact of above items on EPS numerator
                                                         
$
(5,367
)
Impact of above items on EPS denominator
                                                           
(11,301
)

1)
All impacts are shown as pre-tax with aggregate tax effect displayed as "Income tax effects on items above".

       
   
Twelve months ended December 31, 2016
 
   
Cost of Net Revenue
   
Research and Development
   
Selling, General & Administrative
   
Impairment, net of loss on disposition
   
Interest and other income, net
   
Provision for income taxes
   
Equity earnings of unconsolidated entities, net of tax
   
Net Income1
 
                                                 
Amortization of acquisition-related intangible assets
 
$
49,616
   
$
3,685
   
$
127,253
   
$
-
   
$
-
   
$
-
   
$
-
   
$
(180,553
)
Restructuring charges
   
5,991
     
4,052
     
27,831
     
-
     
-
     
-
     
-
     
(37,874
)
Impairment Charges
   
85
     
-
     
193
     
-
     
-
     
-
     
-
     
(278
)
Stock-based compensation expense
   
2,054
     
1,904
     
37,838
     
-
     
-
     
-
     
-
     
(41,796
)
Acquisition-related costs
   
-
     
5,000
     
1,030
     
-
     
-
     
-
     
-
     
(6,030
)
Fair value adjustments to acquisition-related contingent consideration
   
-
     
-
     
(13,308
)
   
-
     
-
     
-
     
-
     
13,308
 
Costs associated with potential business dispositions
   
7
     
-
     
995
     
-
     
-
     
-
     
-
     
(1,002
)
Impairment and (gain) loss on disposition, net
   
-
     
-
     
-
     
(3,810
)
   
-
     
-
     
(29,873
)
   
33,683
 
Amortization - Unconsolidated Subs
   
-
     
-
     
-
     
-
     
-
     
-
     
275
     
(275
)
Audit and legal fees related to on-going governmental investigations
   
-
     
-
     
35,615
     
-
     
4,509
     
-
     
-
     
(40,125
)
Abbott transaction related expenses
   
-
     
-
     
60,266
     
-
     
-
     
-
     
-
     
(60,266
)
INRatio recall expense
   
4,581
     
-
     
-
     
-
     
-
     
-
     
-
     
(4,581
)
Legal settlement accrual
   
-
     
-
     
35,175
     
-
     
-
     
-
     
-
     
(35,175
)
Income tax effects on items above
   
-
     
-
     
-
     
-
     
-
     
(19,303
)
   
-
     
19,303
 
 Total of Supplemental Information
 
$
62,333
   
$
14,641
   
$
312,888
   
$
(3,810
)
 
$
4,509
   
$
(19,303
)
 
$
(29,598
)
 
$
(341,660
)
                                                                 
Impact of above items on EPS numerator
                                                         
$
(1,035
)
Impact of above items on EPS denominator
                                                           
(2,279
)

1)
All impacts are shown as pre-tax with aggregate tax effect displayed as "Income tax effects on items above".

12

Alere Inc. and Subsidiaries
Preliminary Unaudited Reconciliation of Non-GAAP Organic Revenue Growth
(in thousands)

   
Three Months Ended March 31,
   
% Change
 
   
2017
   
2016
     
2017 v. 2016
 
                     
Net revenue
 
$
588,216
   
$
586,940
     
0.2
%
Impact of foreign currency exchange
   
4,770
     
-
         
Impact of acquisitions & dispositions
   
(900
)
   
-
         
Non-GAAP organic net revenue
 
$
592,085
   
$
586,940
     
0.9
%
                         
Arriva Revenue
   
(3,039
)
   
(35,143
)
       
Non-GAAP organic net revenue (excluding Arriva)
 
$
589,046
   
$
551,797
     
6.8
%




 
 
 
 
 
 
 
13

View differences made from one to another to evaluate Alere Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Alere Inc..

Continue

Never Miss A New SEC Filing Again


Real-Time SEC Filing Notifications
Screenshot taken from Gmail for a new 10-K Annual Report
Last10K.com Member Feature

Receive an e-mail as soon as a company files an Annual Report, Quarterly Report or has new 8-K corporate news.

Continue

We Highlighted This SEC Filing For You


SEC Filing Sentiment Analysis - Bullish, Bearish, Neutral
Screenshot taken from Wynn's 2018 10-K Annual Report
Last10K.com Member Feature

Read positive and negative remarks made by management in their entirety without having to find them in a 10-K/Q.

Continue

Widen Your SEC Filing Reading Experience


Increased Reading Area for SEC Filings
Screenshot taken from Adobe Inc.'s 10-Q Quarterly Report
Last10K.com Member Feature

Remove data columns and navigations in order to see much more filing content and tables in one view

Continue

Uncover Actionable Information Inside SEC Filings


SEC Filing Disclosures
Screenshot taken from Lumber Liquidators 10-K Annual Report
Last10K.com Member Feature

Read both hidden opportunities and early signs of potential problems without having to find them in a 10-K/Q

Continue

Adobe PDF, Microsoft Word and Excel Downloads


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshots of actual 10-K and 10-Q SEC Filings in PDF, Word and Excel formats
Last10K.com Member Feature

Export Annual and Quarterly Reports to Adobe PDF, Microsoft Word and Excel for offline viewing, annotations and analysis

Continue

FREE Financial Statements


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshot of actual balance sheet from company 10-K Annual Report
Last10K.com Member Feature

Get one-click access to balance sheets, income, operations and cash flow statements without having to find them in Annual and Quarterly Reports

Continue for FREE

Intrinsic Value Calculator


Intrinsic Value Calculator
Screenshot of intrinsic value for AT&T (2019)
Last10K.com Member Feature

Our Intrinsic Value calculator estimates what an entire company is worth using up to 10 years of financial ratios to determine if a stock is overvalued or not

Continue

Financial Stability Report


Financial Stability Report
Screenshot of financial stability report for Coco-Cola (2019)
Last10K.com Member Feature

Our Financial Stability reports uses up to 10 years of financial ratios to determine the health of a company's EPS, Dividends, Book Value, Return on Equity, Current Ratio and Debt-to-Equity

Continue

Get a Better Picture of a Company's Performance


Financial Ratios
Available Financial Ratios
Last10K.com Member Feature

See how over 70 Growth, Profitability and Financial Ratios perform over 10 Years

Continue

Log in with your credentials

or    

Forgot your details?

Create Account